Amy P. Sing

2.5k total citations · 1 hit paper
32 papers, 1.9k citations indexed

About

Amy P. Sing is a scholar working on Cancer Research, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Amy P. Sing has authored 32 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Cancer Research, 17 papers in Oncology and 8 papers in Pathology and Forensic Medicine. Recurrent topics in Amy P. Sing's work include Breast Cancer Treatment Studies (18 papers), HER2/EGFR in Cancer Research (7 papers) and Cancer Genomics and Diagnostics (7 papers). Amy P. Sing is often cited by papers focused on Breast Cancer Treatment Studies (18 papers), HER2/EGFR in Cancer Research (7 papers) and Cancer Genomics and Diagnostics (7 papers). Amy P. Sing collaborates with scholars based in United States, Greece and South Korea. Amy P. Sing's co-authors include Maura N. Dickler, Beth Overmoyer, Melody Cobleigh, Frankie A. Holmes, Louis Fehrenbacher, Linnea Chap, P. Kelly Marcom, Kathy D. Miller, Virginia K. Langmuir and James D. Reimann and has published in prestigious journals such as Nature, The Journal of Experimental Medicine and Journal of Clinical Oncology.

In The Last Decade

Amy P. Sing

31 papers receiving 1.8k citations

Hit Papers

Randomized Phase III Trial of Capecitabine Compared With ... 2005 2026 2012 2019 2005 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Randomized Phase III Trial of Capecitabine Compared With Bevacizumab Plus Capecitabine in Patients With Previously Treated Metastatic Breast Cancer
    2005 1.0k citations Amy P. Sing et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Amy P. Sing United States 16 1.4k 745 500 435 289 32 1.9k
Lorenzo Gianni Italy 21 1.2k 0.9× 600 0.8× 405 0.8× 526 1.2× 163 0.6× 91 2.0k
Séverine Guiu France 24 1.1k 0.8× 751 1.0× 399 0.8× 464 1.1× 168 0.6× 78 1.9k
Stephen P. Anthony United States 14 881 0.7× 603 0.8× 482 1.0× 368 0.8× 199 0.7× 53 1.5k
S. Shak United States 12 1.1k 0.8× 749 1.0× 609 1.2× 381 0.9× 255 0.9× 40 1.8k
Jean-Marc Extra France 18 1.0k 0.7× 789 1.1× 337 0.7× 333 0.8× 357 1.2× 49 1.7k
Sebastian Aulmann Germany 31 910 0.7× 667 0.9× 1.0k 2.0× 795 1.8× 296 1.0× 74 2.4k
А. Н. Махсон Russia 15 1.2k 0.9× 397 0.5× 310 0.6× 563 1.3× 112 0.4× 23 1.7k
Emer O. Hanrahan United States 14 829 0.6× 560 0.8× 270 0.5× 362 0.8× 236 0.8× 24 1.3k
Marjorie C. Green United States 14 1.7k 1.3× 1.4k 1.9× 328 0.7× 309 0.7× 375 1.3× 19 2.3k
Kristi McIntyre United States 16 1.6k 1.2× 959 1.3× 328 0.7× 405 0.9× 158 0.5× 39 1.9k

Countries citing papers authored by Amy P. Sing

Since Specialization
Citations

This map shows the geographic impact of Amy P. Sing's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amy P. Sing with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amy P. Sing more than expected).

Fields of papers citing papers by Amy P. Sing

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amy P. Sing. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amy P. Sing. The network helps show where Amy P. Sing may publish in the future.

Co-authorship network of co-authors of Amy P. Sing

This figure shows the co-authorship network connecting the top 25 collaborators of Amy P. Sing. A scholar is included among the top collaborators of Amy P. Sing based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amy P. Sing. Amy P. Sing is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bear, Harry D., Wen Wan, André Robidoux, et al.. (2017). Using the 21‐gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: A multicenter trial. Journal of Surgical Oncology. 115(8). 917–923. 70 indexed citations
2.
Mamounas, Eleftherios P., Qing Liu, Soonmyung Paik, et al.. (2017). 21-Gene Recurrence Score and Locoregional Recurrence in Node-Positive/ER-Positive Breast Cancer Treated With Chemo-Endocrine Therapy. JNCI Journal of the National Cancer Institute. 109(4). djw259–djw259. 103 indexed citations
3.
Mamounas, Eleftherios P., Gong Tang, Soonmyung Paik, et al.. (2017). 21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology. Breast Cancer Research and Treatment. 168(1). 69–77. 33 indexed citations
4.
King, Tari A., Jaclyn P. Lyman, Mithat Gönen, et al.. (2016). Prognostic Impact of 21-Gene Recurrence Score in Patients With Stage IV Breast Cancer: TBCRC 013. Journal of Clinical Oncology. 34(20). 2359–2365. 61 indexed citations
5.
Afghahi, Anosheh, Maya B. Mathur, Caroline A. Thompson, et al.. (2016). Use of Gene Expression Profiling and Chemotherapy in Early-Stage Breast Cancer: A Study of Linked Electronic Medical Records, Cancer Registry Data, and Genomic Data Across Two Health Care Systems. Journal of Oncology Practice. 12(6). e697–e709. 11 indexed citations
6.
Alvarado, Michael, Megan Rothney, Diana B. Cherbavaz, et al.. (2015). A Prospective Comparison of the 21-Gene Recurrence Score and the PAM50-Based Prosigna in Estrogen Receptor-Positive Early-Stage Breast Cancer. Advances in Therapy. 32(12). 1237–1247. 31 indexed citations
7.
Yardley, Denise A., N. W. Peacock, Mythili Shastry, et al.. (2015). A phase II trial of ixabepilone and cyclophosphamide as neoadjuvant therapy for patients with HER2-negative breast cancer: correlation of pathologic complete response with the 21-gene recurrence score. Breast Cancer Research and Treatment. 154(2). 299–308. 45 indexed citations
8.
Swain, Sandra M., Raquel Nunes, Carl Yoshizawa, Megan Rothney, & Amy P. Sing. (2015). Quantitative Gene Expression by Recurrence Score in ER-Positive Breast Cancer, by Age. Advances in Therapy. 32(12). 1222–1236. 26 indexed citations
9.
Dixon, J. Michael, Arran Turnbull, Lorna Renshaw, et al.. (2015). Abstract P3-06-35: Association of estrogen receptor (ER) levels and prediction of antiproliferative effect of hormone therapy (HT) in lower ER-expressing tumors. Cancer Research. 75(9_Supplement). P3–6. 1 indexed citations
10.
Alvarado, Michael, Dennis L. Carter, J. Michael Guenther, et al.. (2015). The impact of genomic testing on the recommendation for radiation therapy in patients with ductal carcinoma in situ: A prospective clinical utility assessment of the 12‐gene DCIS score™ result. Journal of Surgical Oncology. 111(8). 935–940. 30 indexed citations
11.
Prasad, C., Megan Rothney, Diana B. Cherbavaz, et al.. (2015). P247 A laboratory comparison of the 21-gene assay and PAM50-ROR. The Breast. 24. S110–S111. 1 indexed citations
12.
Afghahi, Anosheh, Aya Mitani, Manisha Desai, et al.. (2014). Use of the 21-gene recurrence score assay (RS) and chemotherapy (CT) across health care (HC) systems.. Journal of Clinical Oncology. 32(15_suppl). 6580–6580. 1 indexed citations
13.
King, Tari A., Jaclyn P. Lyman, Mithat Gönen, et al.. (2013). Prognostic impact of the 21-gene recurrence score in patients presenting with stage IV breast cancer.. Journal of Clinical Oncology. 31(15_suppl). 507–507. 3 indexed citations
14.
Kabbinavar, Fairooz F., Patrick J. Flynn, Mark Kozloff, et al.. (2012). Gastrointestinal perforation associated with bevacizumab use in metastatic colorectal cancer: Results from a large treatment observational cohort study. European Journal of Cancer. 48(8). 1126–1132. 41 indexed citations
15.
16.
Polite, Blasé N., Amy P. Sing, Daniel J. Sargent, et al.. (2011). Exploring racial differences in outcome and treatment for metastatic colorectal cancer. Cancer. 118(4). 1083–1090. 31 indexed citations
17.
Kozloff, Mark, Jordan Berlin, Patrick J. Flynn, et al.. (2010). Clinical Outcomes in Elderly Patients with Metastatic Colorectal Cancer Receiving Bevacizumab and Chemotherapy: Results from the BRiTE Observational Cohort Study. Oncology. 78(5-6). 329–339. 94 indexed citations
18.
Greenberg, Philip D., et al.. (2007). Genetic Modification of T Cell Clones to Improve the Safety and Efficacy of Adoptive T Cell Therapy. Novartis Foundation symposium. 187. 212–228.
19.
Greenberg, Philip D., Rosalynde J. Finch, Marc A. Gavin, et al.. (1998). Genetic modification of T-cell clones for therapy of human viral and malignant diseases.. PubMed. 4 Suppl 1. S100–5. 15 indexed citations
20.
Reinisch, Carol L., et al.. (1984). Regulation of B cell lymphomagenesis by a malignant Qal+ inducer T cell clone.. The Journal of Experimental Medicine. 159(3). 906–920. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lorenzo Gianni Breakdown of academic impact, for papers by Séverine Guiu Breakdown of academic impact, for papers by Stephen P. Anthony Breakdown of academic impact, for papers by S. Shak Breakdown of academic impact, for papers by Jean-Marc Extra Breakdown of academic impact, for papers by Sebastian Aulmann Breakdown of academic impact, for papers by А. Н. Махсон Breakdown of academic impact, for papers by Emer O. Hanrahan Breakdown of academic impact, for papers by Marjorie C. Green Breakdown of academic impact, for papers by Kristi McIntyre
Rankless by CCL
2026